Haemonetics Corporation
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| HAE | 0YX.F | XVIVO.ST | ITGR | TMDX | GTN0.F | |
|---|---|---|---|---|---|---|
| Market cap | 5.80B | 6.53B | 6.37B | 4.31B | 2.52B | 7.01B |
| P/E (TTM) | 61.6 | 31.0 | 49.4 | 42.5 | 18.8 | 26.3 |
| Forward P/E | 22.1 | — | 34.2 | 18.4 | 32.3 | — |
| Price/book | 6.9 | 2.4 | 2.8 | 2.5 | 4.9 | 0.2 |
| Dividend yield | — | 2.16% | — | — | — | 1.80% |
| 1-year change | +137.15% | +10.05% | +10.74% | +85.72% | −45.89% | +22.84% |
| Today | +5.94% | +2.89% | +0.60% | +0.07% | +8.04% | +3.31% |
The closest companies by business and industry (Medical Devices). Prices may be delayed up to 15 min.
Latest news
All HAE news ›Analysts’ Top Healthcare Picks: Haemonetics (HAE), Climb Bio (CLYM)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Haemonetics (HAE), Climb Bio (CLYM) and Compass Therapeutics (CMPX) with bullish sentiments. In a report released today, Michael Petusky from…
FDA approves berotralstat oral pellets for HAE in patients 12 and up
FDA approves berotralstat 150-mg oral pellets for HAE prophylaxis in patients 12+ who cannot or prefer not to swallow capsules. Adolescents and adults with hereditary angioedema (HAE) who have trouble swallowing capsules now have another…
More from 1 other outlet
Haemonetics Shows Rising Relative Strength; Still Shy Of Key Threshold
A Relative Strength Rating upgrade for Haemonetics shows improving technical performance. Will it continue? Investors.com will undergo scheduled maintenance from 6:00 PM ET to 9:00 PM ET and some features may be unavailable. We apologize…
Haemonetics Hits 80-Plus Relative Strength Rating Benchmark
Haemonetics sees its Relative Strength Rating enter the 80-plus level. Investors.com will undergo scheduled maintenance from 6:00 PM ET to 9:00 PM ET and some features may be unavailable. We apologize for any inconvenience. One important…
FDA approves Orladeyo berotralstat pellets for hereditary angioedema in older age groups
The FDA approved berotralstat oral pellets for prophylactic use in patients aged 12 years and older with hereditary angioedema, according to a press release from BioCryst Pharmaceuticals. As Healio previously reported, the once-daily 150…
Recon: AZ, Oracle partner for AI-powered clinical trials; FDA approves Haemonetics vascular closure system
The complete guide to formulating an effective global regulatory strategy for medical devices, created and curated by experts. Where regulatory professionals collaborate and make connections that last a lifetime. Regulatory Recon is our…
FDA Clears Haemonetics PerQseal Elite Vascular Closure System
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends. FDA Clears Haemonetics PerQseal Elite Vascular Closure System Zero…
More from 4 other outlets
- Vascular News Haemonetics announces US FDA approval of PerQseal Elite vascular closure system
- wincountry.com Haemonetics says FDA clears vascular closure device
- Seeking Alpha Haemonetics wins approval of PerQseal Elite vascular closure system
- @PRNewswire Haemonetics Announces FDA Approval of PerQseal® Elite Vascular Closure System
Haemonetics Gets FDA Approval for Vascular Closure Device
Published on 10/19/2026 at 05:09 pm EDT - Modified on 10/19/2026 at 05:11 pm EDT Haemonetics received approval from U.S. regulators for its PerQseal Elite vascular closure system for use in large-bore arterial procedures. The medical…
Nomogram predicts vascular crisis after free flap surgery
Bioengineer.org Nomogram predicts vascular crisis after free flap surgery Subject of Research: Development and internal validation of a four-factor nomogram for predicting vascular crisis after free flap surgery. Article Title:…
Haemonetics Says CSL Plasma to Complete Rollout of Products by End-2027
Haemonetics said in a filing Thursday that CSL Plasma expects to complete the rollout of Haemonetics' devices and disposables by the end of 2027. CSL expects all of its US plasma collection... Medical Equipment, Supplies & Distribution…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- marketscreener.com9
- investors.com2
- markets.businessinsider.com2
- stockstotrade.com2
- timothysykes.com2
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 31 articles, not a forecast.